Factor Xa Induces Tissue Factor Expression in Endothelial Cells by P44/42 MAPK and NF-κB-Dependent Pathways

被引:22
|
作者
Jiang, Rong [1 ]
Wang, Ning-Ping [2 ]
Tanaka, Kenichi A. [3 ]
Levy, Jerrold H. [3 ]
Guyton, Robert A. [1 ]
Zhao, Zhi-Qing [2 ]
Vinten-Johansen, Jakob [1 ]
机构
[1] Emory Univ, Hosp Midtown, Cardiothorac Res Lab, Carlyle Fraser Heart Ctr,Div Cardiothorac Surg, Atlanta, GA 30322 USA
[2] Mercer Univ, Sch Med Savannah Campus, Dept Biomed Sci, Atlanta, GA USA
[3] Emory Univ, Dept Anesthesiol, Atlanta, GA 30322 USA
关键词
endothelial cell; factor Xa; MAP kinase; NF-kappa B; tissue factor; ACUTE MYOCARDIAL-INFARCTION; COAGULATION-FACTOR XA; SMOOTH-MUSCLE-CELLS; CYTOKINE PRODUCTION; FACTOR GENE; REPERFUSION; THROMBIN; ACTIVATION; INHIBITION; INDUCTION;
D O I
10.1016/j.jss.2010.01.041
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Tissue factor (TF) is an initiator of coagulation. The serine protease factor Xa (FXa) is the convergence point of the extrinsic and intrinsic components of the coagulation cascade. In addition to its hemostatic function, FXa elicits inflammatory responses in endothelial cells that may be important in surgical procedures in which inflammation is triggered. This study tested the hypothesis that FXa can up-regulate TF on vascular endothelial cells by a mitogen-activated protein kinase (MAPK)- and NF-kappa B-dependent pathway. Methods and Results. Incubation of cultured human umbilical vein endothelial cells (HUVECs) with FXa increased TF protein expression and activity in a dose-dependent manner. Pre-incubation of HUVECs with the serine protease inhibitor antithrombin, which targets not only thrombin but also FXa and FIXa, inhibited FXa-induced TF expression, but the selective thrombin inhibitor hirudin did not inhibit FXa-induced TF expression, ruling out a thrombin-mediated pathway. After 10 min incubation with HUVECs, FXa rapidly induced P44/42 MAPK activation (immunoblotting of phosphorylated P44/42 MAPK) with a peak at 30 min. The MEK 1/2 inhibitor PD98059 partially reduced FXa-induced TF expression and activity (3.82 +/- 0.11 vs 6.54 +/- 0.08 fmol/min/cm(2), P < 0.05). NF-kappa B was activated by FXa, confirmed by cytoplasmic IkB alpha degradation and increased NF-kappa B P65 nuclear translocation. Interruption of the NF-kappa B pathway by the IkB alpha phosphorylation inhibitor Bay 11-7802 abrogated FXa-induced TF protein expression and activity (1.93 +/- 0.02 versus 6.54 +/- 0.08 fmol/min/cm(2), P < 0.05). However, inhibition of PI3 kinase by LY 294002 did not attenuate FXa-induced TF protein expression and activity. Conclusions. (1) FXa up-regulates TF protein expression and activity in HUVECs, (2) FXa-induced up-regulation of TF is independent of the thrombin-PAR1 pathway, and (3) the MAPK and NF-kappa B pathways, but not PI3 kinase pathway, are involved in FXa-induced TF expression on human umbilical endothelial cells. FXa may be a feed-forward alternative mechanism of activating TF expression and activity, thereby increasing a procoagulant state or inflammation. This mechanism may be important in the pro-inflammatory state initiated by cardiac surgical procedures. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:319 / 327
页数:9
相关论文
共 50 条
  • [41] Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-κB-dependent pathways
    Jiang, Joy X.
    Mikami, Kenichiro
    Venugopal, Senthil
    Li, Yong
    Torok, Natalie J.
    JOURNAL OF HEPATOLOGY, 2009, 51 (01) : 139 - 148
  • [42] Tetramethylpyrazine Inhibits Platelet Adhesion and Inflammatory Response in Vascular Endothelial Cells by Inhibiting P38 MAPK and NF-κB Signaling Pathways
    Zhang, Han
    Tang, Weiwei
    Wang, Shuang
    Zhang, Junhua
    Fan, Xiang
    INFLAMMATION, 2020, 43 (01) : 286 - 297
  • [43] Cadmium induces matrix metalloproteinase-9 expression via ROS-dependent EGFR, NF-κB, and AP-1 pathways in human endothelial cells
    Lian, Sen
    Xia, Yong
    Pham Ngoc Khoi
    Trong Thuan Ung
    Yoon, Hyun Joong
    Kim, Nam Ho
    Kim, Kyung Keun
    Jung, Young Do
    TOXICOLOGY, 2015, 338 : 104 - 116
  • [44] Epithelial Cells in vitro Induces Mesenchymal Stem Cell Migration through an NF-κB-Dependent Pathway
    Ferrand, Jonathan
    Lehours, Philippe
    Schmid-Alliana, Annie
    Megraud, Francis
    Varon, Christine
    PLOS ONE, 2011, 6 (12):
  • [45] Thrombin induces inducible nitric oxide synthase expression via the MAPK, MSK1, and NF-κB signaling pathways in alveolar macrophages
    Lin, Chen-Chun
    Shih, Chung-Huang
    Yang, You-Lan
    Bien, Mauo-Ying
    Lin, Chien-Huang
    Yu, Ming-Chih
    Sureshbabu, Munisamy
    Chen, Bing-Chang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 672 (1-3) : 180 - 187
  • [46] Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells
    Seo, Ok-Won
    Kim, Jung Hwan
    Lee, Kwang-Soon
    Lee, Kyu-Sun
    Kim, Ji-Hee
    Won, Moo-Ho
    Ha, Kwon-Soo
    Kwon, Young-Guen
    Kim, Young-Myeong
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2012, 44 (11) : 653 - 664
  • [47] High glucose levels increase the expression of neurotrophic factors associated with p-p42/p44 MAPK in Schwann cells in vitro
    Zhu, Hao
    Yu, Wen-Juan
    Le, Yan
    Wang, Wen-Jin
    Li, Feng
    Gui, Ting
    Wang, Yue-Ming
    Shi, Wo-Dong
    Ding, Wen-Long
    Fan, Xian-Qun
    MOLECULAR MEDICINE REPORTS, 2012, 6 (01) : 179 - 184
  • [48] Activation of NF-κB nuclear transcription factor by flow in human endothelial cells
    Hay, DC
    Beers, C
    Cameron, V
    Thomson, L
    Flitney, FW
    Hay, RT
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2003, 1642 (1-2): : 33 - 44
  • [49] Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-κB and AP-1
    Yang, Xinyu
    Li, Lin
    Liu, Jin
    Lv, Ben
    Chen, Fangping
    THROMBOSIS RESEARCH, 2016, 137 : 211 - 218
  • [50] Cardioprotective effects of transforming growth factor-β1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK
    Baxter, GF
    Mocanu, MM
    Brar, BK
    Latchman, DS
    Yellon, DM
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 38 (06) : 930 - 939